At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,636 enrolled
Drug / intervention
No intervention will take place for this retrospective and observational study.other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival
In Brief
An observational study evaluating No intervention will take place for this retrospective and observational study. for Coronary Artery Disease. Completed, enrolled 2,636 participants.
Detailed Summary
An investigator-driven, retrospective study to compare long-term survival-data (10-year follow-up) of patients with coronary artery disease (CAD), previously enrolled in the SYNTAX trial, who were randomized to percutaneous coronary intervention (PCI) using a paclitaxel (TAXUS) drug-eluting-stent (DES) or coronary artery bypass grafting (CABG).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2018
Primary CompletionAug 2019
TodayJul 2026
First PostedJan 31, 2018
Enrollment StartDec 1, 2016
Primary CompletionAug 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.4 years ago
Interventions
No intervention will take place for this retrospective and observational study.other
No intervention will take place for this retrospective and observational study.